[go: up one dir, main page]

WO1996037605A3 - OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE - Google Patents

OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE Download PDF

Info

Publication number
WO1996037605A3
WO1996037605A3 PCT/FR1996/000785 FR9600785W WO9637605A3 WO 1996037605 A3 WO1996037605 A3 WO 1996037605A3 FR 9600785 W FR9600785 W FR 9600785W WO 9637605 A3 WO9637605 A3 WO 9637605A3
Authority
WO
WIPO (PCT)
Prior art keywords
sense oligonucleotides
ige receptor
anti sense
receptor synthesis
blocking ige
Prior art date
Application number
PCT/FR1996/000785
Other languages
English (en)
Other versions
WO1996037605A2 (fr
Inventor
Eduardo Pirotzky
Soudhir Colote
Original Assignee
Scras
Eduardo Pirotzky
Soudhir Colote
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scras, Eduardo Pirotzky, Soudhir Colote filed Critical Scras
Priority to US08/952,597 priority Critical patent/US5892023A/en
Priority to EP96917549A priority patent/EP0828827A2/fr
Priority to AU60082/96A priority patent/AU6008296A/en
Publication of WO1996037605A2 publication Critical patent/WO1996037605A2/fr
Publication of WO1996037605A3 publication Critical patent/WO1996037605A3/fr
Priority to NO975423A priority patent/NO975423L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/337—Chemical structure of the base in alpha-anomeric form
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des oligonucléotides antisens qui hybrident sélectivement avec un ou plusieurs gènes nécessaires à bloquer la synthèse du récepteur de l'IgE, des compositions pharmaceutiques les contenant et leur utilisation pour la préparation de médicaments pour le traitement d'allergies.
PCT/FR1996/000785 1995-05-26 1996-05-24 OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE WO1996037605A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/952,597 US5892023A (en) 1995-05-26 1996-05-24 Anti sense oligonucleotides for blocking IgE receptor synthesis
EP96917549A EP0828827A2 (fr) 1995-05-26 1996-05-24 OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE
AU60082/96A AU6008296A (en) 1995-05-26 1996-05-24 Anti sense oligonucleotides for blocking ige receptor synthe sis
NO975423A NO975423L (no) 1995-05-26 1997-11-25 Anti-sense oligonukleotider for blokkering av IgE-reseptorsyntese

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9510718.1 1995-05-26
GBGB9510718.1A GB9510718D0 (en) 1995-05-26 1995-05-26 Antisense oligonucleotides

Publications (2)

Publication Number Publication Date
WO1996037605A2 WO1996037605A2 (fr) 1996-11-28
WO1996037605A3 true WO1996037605A3 (fr) 1996-12-27

Family

ID=10775100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1996/000785 WO1996037605A2 (fr) 1995-05-26 1996-05-24 OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE

Country Status (7)

Country Link
US (1) US5892023A (fr)
EP (1) EP0828827A2 (fr)
AU (1) AU6008296A (fr)
CA (1) CA2222197A1 (fr)
GB (1) GB9510718D0 (fr)
NO (1) NO975423L (fr)
WO (1) WO1996037605A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408011A1 (fr) * 2000-05-04 2001-11-08 Avi Biopharma, Inc. Composition anti-sens a region d'epissage et methode associee
CA2499073C (fr) * 2002-09-16 2013-07-23 Commvault Systems, Inc. Systeme et methode de copie auxiliaire a flux combine
CA2532795A1 (fr) * 2003-08-07 2005-02-17 Avi Biopharma, Inc. Compose antiviral sens et methode permettant de traiter une infection virale induite par un arnss
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
CA2553104A1 (fr) * 2004-01-23 2005-08-11 Avi Biopharma, Inc. Oligomeres antisens et methodes destinees a induire la tolerance immunitaire et l'immunosuppression
EP1737956A2 (fr) * 2004-03-01 2007-01-03 Massachusetts Institute of Technology Agents therapeutiques a base d'arni pour le traitement de la rhinite allergique et de l'asthme
PT1766010E (pt) 2004-06-28 2011-05-25 Univ Western Australia Oligonucle?tidos antisense para a indu??o de skipping de ex?es e seus m?todos de utiliza??o
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
WO2006085973A2 (fr) * 2004-07-02 2006-08-17 Avi Biopharma, Inc. Technique et compose antibacterien antisens
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8329668B2 (en) * 2005-09-08 2012-12-11 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007030691A2 (fr) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Compose antisens antiviral et procede de traitement d'infection picornavirale
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
DK2024499T3 (da) 2006-05-10 2018-01-29 Sarepta Therapeutics Inc Oligonukleotidanaloger med kationiske intersubunit-koblinger
EP2235034B1 (fr) * 2007-12-28 2016-11-23 Sarepta Therapeutics, Inc. Agents immunomodulatoires et procédés d'utilisation
KR20180011364A (ko) 2008-10-24 2018-01-31 사렙타 쎄러퓨틱스 인코퍼레이티드 Dmd를 위한 다중 엑손 스키핑 조성물
CA2746508A1 (fr) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Compositions antisens et methodes de modulation de l'hypersensibilite de contact ou de la dermatite de contact
PT2499249T (pt) 2009-11-12 2018-11-21 Univ Western Australia Moléculas antisentido e métodos para tratar patologias
CN107312777B (zh) 2009-11-13 2020-11-13 萨雷普塔治疗公司 反义抗病毒化合物及治疗流感病毒感染的方法
EP2576574A2 (fr) 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Analogues oligonucléotidiques ayant des liaisons modifiées entre sous-unités et/ou des groupes terminaux modifiés
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2012031243A2 (fr) 2010-09-03 2012-03-08 Avi Biopharma, Inc. Molécules d'arnds comportant des analogues oligonucléotidiques ayant des liaisons entre sous-unités et/ou des groupes terminaux modifiés
KR102271212B1 (ko) 2011-11-18 2021-07-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
NZ631245A (en) 2013-03-14 2017-09-29 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
EP3662912A1 (fr) 2013-03-15 2020-06-10 Sarepta Therapeutics, Inc. Dosages d'eteplirsen améliorés pour le traitement de la dystrophie musculaire de duchenne
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021317A1 (fr) * 1992-04-16 1993-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ISOLATION, CARACTERISATION ET UTILISATION DE LA SOUS-UNITE HUMAINE β DU RECEPTEUR DE HAUTE AFFINITE POUR L'IMMUNOGLOBULINE E
WO1995009002A1 (fr) * 1993-09-30 1995-04-06 University Of Pennsylvania Methode d'inhibition de la phagocytose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021317A1 (fr) * 1992-04-16 1993-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ISOLATION, CARACTERISATION ET UTILISATION DE LA SOUS-UNITE HUMAINE β DU RECEPTEUR DE HAUTE AFFINITE POUR L'IMMUNOGLOBULINE E
WO1995009002A1 (fr) * 1993-09-30 1995-04-06 University Of Pennsylvania Methode d'inhibition de la phagocytose

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BHATTI, L. ET AL.: "Inhibition of B cell proliferation by antisense DNA to both alpha and beta forms of Fc epsilon R II.", CELL IMMUNOL, (1992 OCT 1) 144 (1) 117-30, XP000561855 *
FOURNIER, S. ET AL.: "Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation.", BLOOD, (1994 SEP 15) 84 (6) 1881-6., XP000609085 *
FU-TONG, LIU ET AL.: "CDNA HETEROGENEITY SUGGESTS STRUCTURAL VARIANTS RELATED TO THE HIGH-AFFINITY IGE RECEPTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, no. 15, pages 5639 - 5643, XP000005253 *
ZON, G.: "Oligonucleotide analogues as potential chemotherapeutic agents", PHARMACEUTICAL RESEARCH, VOL. 5 (1988); 539 - 549, XP002008915 *

Also Published As

Publication number Publication date
AU6008296A (en) 1996-12-11
NO975423D0 (no) 1997-11-25
NO975423L (no) 1997-11-25
EP0828827A2 (fr) 1998-03-18
US5892023A (en) 1999-04-06
CA2222197A1 (fr) 1996-11-28
WO1996037605A2 (fr) 1996-11-28
GB9510718D0 (en) 1995-07-19

Similar Documents

Publication Publication Date Title
WO1996037605A3 (fr) OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE
ZA964738B (en) Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
IL122484A0 (en) Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
NO973922D0 (no) Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
NO20002113L (no) Nye tricykliske forbindelser og deres anvendelse i medisin, fremgangsmÕte for deres fremstillling og farmasøytiske sammensetninger inneholdende dem
IL161829A (en) 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators
HUP9904046A3 (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing the same
CA2190588A1 (fr) Analogues de nucleotides de pteridine sous forme d'echantillons d'adn fluorescents
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
WO2002099051A3 (fr) Nit utilises comme modificateurs de la voie p53 et procedes d'utilisation
WO1995011912A3 (fr) Synthese de biopolymeres utilisant des polymeres organiques actives en surface
TR200200137T2 (tr) Nükleotid analog kompozisyonlar.
WO2001047944A3 (fr) Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants
WO2001087227A3 (fr) Methodes et compositions a base de micelles polymeres sensibles au ph, permettant d'augmenter la puissance d'agents therapeutiques
AU1062997A (en) Novel polymer supports for nucleic acid synthesis
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
WO1997004788A3 (fr) Utilisation de glycosides de calendula dans le traitement du psoriasis
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
ATE170854T1 (de) Heterocyclische, aromatische verbindungen, pharmazeutische und kosmetische zusammensetzungen,die sie enthalten, und verwendungen.
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
EP0775745A3 (fr) Aptamères capables d'inhiber la cathépsine G
NO305948B1 (no) Basisk substituerte benzolguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum samt medikament inneholdende forbindelsen
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
TR199600118A2 (tr) Sübstitüe edilmis benzolsulfonil üreler ve tioüreler, bunlarin üretilmesine mahsus usul, ilac veya diyagnostik olarak kullanilmalari ve bunlari ihtiva eden ilac.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08952597

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2222197

Country of ref document: CA

Ref country code: CA

Ref document number: 2222197

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996917549

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996917549

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996917549

Country of ref document: EP